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Abstract
Scrub typhus (caused by Orientia tsutsugamushi) and murine typhus (caused by Rickettsia typhi) cause up to 28% of febrile episodes in
Thailand and Laos. The current understanding of coagulation and inflammation in the pathogenesis of these clinically very similar vascu-
lotropic diseases is limited. This study compared human in vivo changes in 15 coagulation, inflammation and endothelial activation mark-
ers in prospectively collected admission and follow-up samples of 121 patients (55 scrub typhus, 55 murine typhus, and 11 typhus-like
illness) and 51 healthy controls from Laos. As compared with controls, all but one of the markers assessed were significantly affected in
typhus patients; however, the activation patterns differed significantly between scrub and murine typhus patients. The levels of markers
of coagulation activation and all inflammatory cytokines, except for interleukin-12, were significantly higher in patients with scrub typhus
than in those with murine typhus. In patients with murine typhus, however, the levels of endothelium-derived markers were significantly
higher. Anticoagulant factors were inhibited in both typhus patient groups. This is the first study demonstrating that, in scrub typhus,
in vivo coagulation activation is prominent and is related to a strong proinflammatory response, whereas in murine typhus, changes in
coagulant and fibrinolytic pathways are suggestive of endothelial cell perturbation. These data suggest that, although late-stage endothe-
lial infection is common in both diseases, the in vivo pathogenic mechanisms of R. typhi and O. tsutsugamushi could differ in the early
phase of infection and may contribute to disease differentiation.
Keywords: Coagulation, inflammation, Laos, murine typhus, pathophysiology, scrub typhus, vasculitis
Original Submission: 28 September 2011; Revised Submission: 1 November 2011; Accepted: 3 November 2011
Editor: D. Raoult
Article published online: 7 November 2011
Clin Microbiol Infect 2012; 18: 1221–1228
10.1111/j.1469-0691.2011.03717.x
Corresponding author: D. H. Paris, Mahidol–Oxford Tropical
Medicine Research Unit (MORU), 3rd Floor, 60th Anniversary Chal-
ermprakiat Building, Faculty of Tropical Medicine, Mahidol University,
420/6 Rajvithee Rd, Bangkok 10400, Thailand
E-mail: parigi@tropmedres.ac
Introduction
Rickettsial diseases are important and under-recognized
causes of morbidity and mortality in Southeast Asia.
Whereas Rocky Mountain spotted fever (caused by Rickettsia
rickettsii) and Mediterranean spotted fever (Rickettsia conorii)
are prevalent in the western hemisphere and the Mediterra-
nean basin, scrub typhus (Orientia tsutsugamushi) and murine
typhus (Rickettsia typhi) are responsible for the majority of
rickettsial diseases in Asia, and cause up to 28% of febrile
episodes in Thailand and the Lao People’s Democratic
Republic (Laos) [1,2]. An increasing proportion of returning
travellers are at risk of acquiring scrub or murine typhus [3].
The true incidence of these diseases is likely to be underesti-
mated, owing to suboptimal diagnostic tools [4] and the
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limited availability of epidemiological data. Patients with
scrub or murine typhus commonly present with fever and
non-specific symptoms, but both diseases can be complicated
by meningoencephalitis, disseminated intravascular coagula-
tion (DIC), or severe pneumonitis, which may culminate in
acute respiratory distress syndrome [5].
The cellular tropism for spotted fever group and typhus
group Rickettsia has been shown to be mainly endothelial [6,7],
and observations in scrub typhus point to the endothelium as
the main site of late-stage infection [8], but in vivo data are
lacking. Recent findings of significantly raised in vivo levels of
soluble L-selectins in scrub typhus patients [9] suggest mono-
nuclear cell activation rather than endothelial activation at the
hospital admission time-point, which may represent O. tsutsuga-
mushi tropism during early dissemination, or local immune acti-
vation within the eschar and draining lymph nodes.
The current study was aimed at comparing in vivo levels of
coagulation and inflammation markers in patients with acute
murine typhus and acute scrub typhus in order to under-




A total of 248 non-pregnant patients with clinical suspicion
of scrub typhus or murine typhus were prospectively
recruited at Mahosot Hospital, Vientiane, Lao PDR. Of these,
121 patients with paired positive dynamic serology findings
were randomly selected, including 55 patients with scrub
typhus, 55 patients with murine typhus, 11 ‘febrile controls’
with clinical suspicion of typhus, but negative paired serology
and PCR results for scrub and murine typhus, and 51 local
contemporary blood donors as healthy controls.
Ethics statement
The study was approved by the National Ethics Committee for
Health Research, Ministry of Public Health, Lao PDR, and the
Oxford Tropical Research Ethics Committee, UK. All patients
gave written informed consent prior to sample collection.
Investigations
On admission, a full physical examination and the following
panel of investigations were performed: complete blood
count, haematological and biochemical markers (Table 1),
indirect immunofluorescence assays (IFAs), PCR assays, and
coagulation (ELISA) and cytokine markers (flowcytometric
assay (FACS)). All follow-up samples, which were available
for all patients, were processed for IFA, coagulation and
cytokine measurements.
Serological diagnosis
The definitive diagnoses of scrub typhus and murine typhus
were based on a ‡4-fold dynamic rise in IgM and IgG IFA
titres for paired serum samples, which represents the cur-
rent serological reference standard [4]. Slides prepared and
standardized by the Australian Rickettsial Reference Labora-
TABLE 1. Demographic, clinical and laboratory characteristics of patients
Parameter Unit Scrub typhus Murine typhus p-value (ST vs. MT) Febrile controls
Age Years (range) 26 (5–75) 31 (9–82) 0.13 27 (16–65)
Days of fevera Days (IQR) 8.5 (7–11) 8 (7–10) 0.54 8 (7–15)
ADM-FUPb Days (IQR) 6 (4–7) 6 (4–7) 0.50 3 (3–6)
Eschar No. (%) 23/54 (43) 0/55 (0) 0.0001 2/11 (18)
Skin rash No. (%) 10/54 (19) 10/54 (19) 0.93 3/11 (27)
Lymphadenopathyc No. (%) 34/54 (63) 3/54 (6) 0.0001 0 (0)
Haemorrhaged No. (%) 22/55 (40) 5/55 (9) 0.0002 3/8 (38)
Hearing loss No. (%) 24/30 (80) 0/15 (0) 0.07 1/8 (13)
GCS Score (IQR) 15 (15–15) 15 (15–15) 0.32 15 (15–15)
WBC ·103/mL (IQR) 9.6 (6.5–12.80) 8.5 (6.8–10.7) 0.49 7.3 (6.2–7.9)
Lymphocytes % WBC (IQR) 30 (22–40) 33 (27–40) 0.34 36 (33–41)
Monocytes % WBC (IQR) 4.5 (0–9) 1 (0–4) 0.62 0.5 (0–1)
Platelets 1000/mL (IQR) 209 (182–225) 200 (170–210) 0.11 210 (170–250)
Sodium mmol/L (IQR) 137 (132–143) 145 (139–151) 0.0003 145 (141–148)
Creatinine lmol/L (IQR) 88.4 (70.7–114.9) 106.1 (88.4–123.8) 0.006 106.1 (97.2–132.6)
Albumin g/dL (IQR) 3.3 (2.7–3.7) 3.9 (3.3–4.2) 0.0002 4.2 (3.6–4.9)
Blood urea nitrogen mmol/L (IQR) 3.93 (3.21–5.0) 3.2 (2.5–5.0) 0.11 3.57 (2.5–3.9)
Aspartate transaminase U/L (IQR) 84 (52–130) 75 (44–102) 0.24 64 (22–89)
C-reactive protein U/L (IQR) 81 (46–131) 48 (30–113) 0.05 2 (1–64)
Lactate dehydrogenase U/L (IQR) 514 (389–626) 429 (324–555) 0.03 389 (274–546)
ADM-FUP, time between admission and follow-up; GCS, Glasgow Coma Scale; IQR, interquartile range; MT, murine typhus; ST, scrub typhus; WBC, white blood cell count.
Comparisons of demographic, clinical, haematological and biochemical parameters for scrub typhus (n = 55), murine typhus (n = 55) and febrile controls (n = 11). Significant
p-values are depicted in bold. Probability values were calculated with the Kruskal–Wallis equality-of-populations rank test.
aRepresents the number of febrile days before admission.
bThe admission to follow-up period for cytokine, coagulation and biochemistry parameters (not identical to the period between paired diagnostic samples for serology).
cRegional and/or generalized lymphadenopathy.
dThe criteria for ‘haemorrhage’ were defined as (muco)cutaneous petechial and suffusion bleeding sites.
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tory were used for anti-O. tsutsugamushi antibody detection
(using pooled Karp, Kato and Gilliam antigens) and anti-R. ty-
phi antibody detection (R. typhi Wilmington strain antigens).
Molecular diagnosis
On admission, bacteraemic patients were identified by real-
time PCR, targeting the groEL gene for scrub typhus [10] and
the ompB gene for murine typhus [11], as previously
described, with modification of the endpoint visualization by
intercalating SYBR green [12]. DNA templates were
extracted from 200 lL of buffy coat collected from EDTA-
anticoagulated full blood samples (Qiagen Mini Blood kit;
Qiagen, Germantown, MD, USA).
Cytokines
The plasma concentrations of inflammatory cytokines
(Table 2) were measured by flow-cytometric bead assay
according to the manufacturer’s instructions
(Cat. No. 551811; BD Biosciences, San Jose, CA, USA). The
detection limit for each analyte was determined by use of a
serial dilution of the provided recombinant standard to gen-
erate a standard curve (curve-fitting model; four-parameter
logistic): 2.9 pg/mL for interleukin (IL)-12, 4.8 pg/mL for
tumour necrosis factor-a (TNF-a) and IL-1b, 5.4 pg/mL for
IL-6, 4.5 pg/mL for IL-8, and 4.6 pg/mL for IL-10.
Markers of coagulation, fibrinolysis, and endothelium
activation
Thrombin–antithrombin (TAT) complexes, soluble tissue fac-
tor (sTF), plasminogen activator inhibitor-1 (PAI-1), tissue-
type plasminogen activator (tPA), plasminogen activator
activity (PAA), antithrombin (AT), protein C (PC), soluble
thrombomodulin (sTM) and von Willebrand factor (VWF)
were measured in all samples. TAT complexes, sTF, tPA and
sTM concentrations were measured with commercially avail-
able ELISAs (TAT complexes, Behringwerke AG, Marburg,
Germany; sTF, American Diagnostics, Greenwich, CT, USA;
tPA and sTM, Diagnostica Stago, Asnie`res-sur-Seine, France).
AT, PAA and PAI-1 activities were measured with automated
amidolytic techniques. PC activity was determined with an
amidolytic assay using chromogenic substrate S2366 (Chro-
mogenix, Milan, Italy). VWF antigen was assessed by ELISA
with commercial antibodies (Dako, Glastrup, Denmark), as
described previously [13].
Statistical analysis
Results are reported as medians and interquartile ranges,
unless otherwise specified. Patient groups were compared by
use of the Kruskal–Wallis test. All statistical analyses, includ-
ing receiver operating characteristic curves of coagulation
parameters, were calculated with Stata/MP 11.0 (Stata Corp.,
College Station, TX, USA).
Results
Demographic, clinical and laboratory characteristics of
patients
The median intervals (interquartile range) between admission
and convalescent serology were 7 days (5–12 days) for scrub
TABLE 2. Markers of coagulation and inflammation on admission in patients and controls
Parameter Unit
Median (IQR) p-values
ST MT FC HC ST vs. MT ST vs. FC MT vs. FC
Typhus vs.
Controls
TAT complexes ng/mL 18.2 (16.9–19.3) 11.6 (10.6–12.9) 6.8 (5.7–8.2) 3.8 (3.0–4.8) 0.0001 0.0001 0.0001 0.0001
sTF pg/mL 538 (467–587) 298 (276–326) 87 (72–98) 43 (32–59) 0.0001 0.0001 0.0001 0.0001
sTM ng/mL 228 (203–254) 498 (456–537) 113 (105–123) 91 (84–102) 0.0001 0.0001 0.0001 0.0001
VWF % 176 (143–201) 302 (276–361) 112 (104–125) 103 (89–111) 0.0001 0.0004 0.0001 0.0001
AT % 89 (84–95) 104 (98–110) 101 (98–103) 103 (98–108) 0.0001 0.0013 0.255 0.0007
PC % 99 (93–105) 82 (75–88) 102 (98–108) 102 (94–107) 0.0001 0.3053 0.0001 0.0001
PAI-1 ng/mL 12.8 (11.5–16.6) 20.5 (16.8–23.8) 7.8 (6.4–9.1) 5.2 (3.7–6.8) 0.0001 0.0001 0.0001 0.0001
PAA % 92 (89–94) 84 (80–88) 103 (102–107) 102 (94–106) 0.0001 0.0001 0.0001 0.0001
tPA ng/mL 11.4 (8.6–13.7) 16.4 (14.8–18.9) 7.1 (5.9–8.2) 4.7 (3.7–5.9) 0.0001 0.0008 0.0001 0.0008
TNF-a pg/mL 1.4 (1.1–2.4) 0 (0–1.3) 1.3 (0–2.7) 0 (0–1.1) 0.0003 0.985 0.069 0.01
IL-1b pg/mL 0 (0–3.5) 0 (0–0) 0 (0–2.8) 0 (0–0) 0.0002 0.931 0.005 0.16
IL-6 pg/mL 17.7 (12.1–37.2) 12.7 (7.7–23.3) 7.9 (2.2–20.8) 0 (0–1.3) 0.02 0.178 0.02 0.0001
IL-8 pg/mL 17.5 (12.6–26.1) 11.5 (8.0–24.6) 13.1 (4.3–27.4) 4.6 (3.1–6.9) 0.04 0.167 0.654 0.0001
IL-10 pg/mL 13.5 (6.4–25.9) 3.0 (1.6–4.8) 4.1 (0–13.4) 0 (0–0) 0.0001 0.036 0.69 0.0001
IL-12 pg/mL 1.7 (0–2.4) 1.6 (0–2.2) 1.3 (0–1.7) 1.3 (0–1.9) 0.42 0.39 0.59 0.03
AC, all controls; AT, antithrombin; FC, febrile controls; HC, healthy controls; IL, interleukin; IQR, interquartile range; MT, murine typhus group; PAA, plasminogen activator
activity; PAI-1, plasminogen activator inhibitor-1; PC, protein C; ST, scrub typhus group; sTF, soluble tissue factor; sTM, soluble thrombomodulin; TAT, thrombin–antithrom-
bin; TNF-a, tumour necrosis factor-a; tPA, tissue-type plasminogen activator; VWF, von Willebrand factor.
Results of admission samples only. Probability values were calculated with the Kruskal–Wallis equality-of-populations rank test. Sample sizes for coagulation parameters: ST,
n = 55; MT, n = 55; FC, n = 11; HC, n = 51. Sample sizes for cytokines: ST, n = 51; MT, n = 49; FC, n = 11; HC, n = 45.
Significant p-values are depicted in bold.
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typhus patients, 8 days (5–14 days) for murine typhus
patients, and 6 days (4–13 days) for febrile controls (p 0.7)
(Table 1). The proportions of patients with bacteraemia
were 47/55 (85%) in scrub typhus patients and 43/55 (78%)
in murine typhus patients. All typhus patients survived to dis-
charge, had similar histories of ‘duration of fever’ prior to
admission, and had similar demographic and haematological
parameters. Laboratory parameters that differed between
the two typhus groups were plasma sodium, creatinine, albu-
min, C-reactive protein (CRP) and lactate dehydrogenase
(Table 1), although sodium and creatinine values remained
within the normal range for both groups. On the basis of
these data, the disease severity did not appear to differ sig-
nificantly between the two patient groups, allowing for direct
comparisons.
Upon admission, three clinical features were significantly
associated with scrub typhus: the presence of eschar
(p <0.001), lymphadenopathy (p <0.001), and mucosal/skin
haemorrhages (p <0.001). Hearing loss was only observed in
patients with scrub typhus (p 0.07), whereas skin rash was
observed in equal proportions in both forms of typhus.
Markers of coagulation, fibrinolysis, and endothelium
activation
The plasma levels of all markers were significantly different
in patients with scrub or murine typhus than in controls,
except for AT in patients with murine typhus and PC in
patients with scrub typhus. However, the activation patterns
differed significantly between the two patient groups
(Table 2). Coagulation activation, with high plasma concen-
trations of TAT complexes and sTF, was more pronounced
in patients with scrub typhus than in patients with murine
typhus (p <0.001) (Fig. 1).
Overall anticoagulant activity was decreased in both
typhus groups: in patients with scrub typhus, but not in
those with murine typhus, AT levels were significantly
decreased (p <0.001, p 0.8), whereas PC levels were signifi-
cantly lower in patients with murine typhus, but not in those
with scrub typhus (p <0.001 and p 0.3) (Fig. 2).
Levels of endothelial cell-derived tPA were higher in
patients with murine typhus than in those with scrub typhus.
PAA levels were decreased in both typhus groups as com-
pared with healthy controls, but the decrease was more pro-
nounced in patients with murine typhus, corresponding with
increased PAI-1 levels in these patients (Fig. 3). Plasma con-
centrations of sTM and VWF were elevated in both typhus
groups as compared with controls, but the increases were
significantly more prominent in patients with murine typhus
(p <0.001 for both indices) (Fig. 4).
Markers of inflammation
In patients with scrub typhus, the levels of all cytokines mea-
sured were significantly raised as compared with healthy
controls, whereas in patients with murine typhus, the levels
of all except IL-1b were raised. Plasma levels of IL-6, IL-8
and, particularly IL-10, were markedly higher in patients with
scrub typhus than in those with murine typhus (Table 2). On
admission, TNF-a and IL-1b levels were low in both typhus
patient groups: 39/51 (76%) and 18/51 (35%) of patients with
scrub typhus had detectable levels of TNF-a and IL-1b,
respectively, and 23/49 (47%) and 3/49 (6%) of patients with
murine typhus had detectable levels of TNF-a and IL-1b,
respectively. Because of an expected proportion of TNF-a
and IL-1b levels being under the limit of detection, the
resulting medians for both groups could be 0, although the
proportions of detectable levels differed sufficiently to allow
the generation of a statistically significant p-value (both
p £0.001).
Power of prediction/discrimination
All coagulation markers were further evaluated for their diag-
nostic potential and ability to correctly classify patients with
FIG. 1. Markers of coagulation. Levels of thrombin–antithrombin (TAT) complexes and soluble tissue factor (sTF) were significantly higher in
patients with scrub typhus (ST), murine typhus (MT) and scrub and murine typhus combined (SMT) than in febrile controls (FC) or healthy con-
trols (HC). On comparison of ST and MT, TAT complexes and sTF levels were significantly higher in ST. Data are expressed as mean and inter-
quartile range (grey boxes) and upper and lower adjacent values (whiskers) of admission samples. *Odds ratios (95% CIs): TAT complexes, 0.24
(0.13–0.44); sTF, 0.89 (0.78–1.01).
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either form of typhus (healthy controls were excluded). Only
TAT complexes, sTF, VWF, sTM and tPA demonstrated suffi-
cient discrimination, with areas under the receiver operating
characteristic curves of >0.9. Of these, TAT complexes and
sTF correctly classified scrub typhus patients at the optimal
cut-offs of ‡14.6 ng/mL and ‡387 pg/mL in 94.2% and 97.5%
of the cohort, respectively, and VWF, sTM and tPA correctly
classified murine typhus patients at the optimal cut-offs of
‡256%, ‡378 ng/mL and ‡14.5 ng/mL in 87.6%, 97.5% and
86.0% of the cohort, respectively (Table S1; Fig. S2).
FIG. 2. Anticoagulant factors. On admission, anticoagulant pathways were inhibited in patients with scrub typhus (ST), murine typhus (MT) and
scrub and murine typhus combined (SMT) as compared with controls. Antithrombin (AT) levels were significantly decreased in ST but not in
MT, whereas protein C (PC) levels were significantly lower in MT, but not in ST, than in healthy controls (HC). Data are depicted as mean and
interquartile range (grey boxes) and upper and lower adjacent values (whiskers). *Odds ratios (95% CI): AT, 1.17 (1.1–1.24); PC, 0.80 (0.73–
0.87). FC, febrile controls.
FIG. 3. Markers of fibrinolytic activity. Although, on admission, levels of tissue-type plasminogen activator (tPA) and plasminogen activator inhibi-
tor-1 (PAI-1) were significantly raised, overall plasminogen activator activity (PAA) was significantly lower in patients with murine typhus (MT)
than in those with scrub typhus (ST). Data are expressed as mean and interquartile range (grey boxes) and upper and lower adjacent values
(whiskers). *Odds ratios (95% CIs): tPA, 1.69 (1.39–2.05); PAI-1, 1.39 (1.23–1.57); PAA, 0.78 (0.71–0.86). FC, febrile controls; HC, healthy con-
trols; SMT, scrub and murine typhus combined.
FIG. 4. Markers of endothelial cell perturbation. On admission, plasma concentrations of endothelium-derived soluble thrombomodulin (sTM)
and von Willebrand factor (VWF) were significantly higher in patients with murine typhus (MT) than in those with scrub typhus (ST). Data are
depicted as mean and interquartile range (grey boxes) and upper and lower adjacent values (whiskers). *Odds ratios (95% CIs): VWF and sTM,
1.03 (1.02–1.04). FC, febrile controls; HC, healthy controls; SMT, scrub and murine typhus combined.
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Response to treatment
After treatment with doxycycline (100 mg twice daily for
7 days following a 200-mg loading dose), the levels of all 15
coagulation and cytokine markers tended to return to those
observed in healthy controls (Fig. S1; cytokine data not
shown). Normalization of these parameters coincided with
clinical improvement in response to antibiotic therapy.
Discussion
To our knowledge, this is the first study to compare mark-
ers of coagulation and inflammation in sympatric scrub
typhus and murine typhus patients in the same population.
This study from Laos demonstrates that all markers of coag-
ulation, fibrinolysis and endothelium activation are signifi-
cantly affected in both typhus groups as compared with
healthy controls, and that the coagulation profiles of scrub
and murine typhus patients are profoundly different
(Table 2).
Both typhus forms demonstrated similar disease severities
and complication rates, but the levels of albumin (reduced,
but within the normal range) and CRP (elevated) in patients
with scrub typhus suggest that inflammation might play a
more important role in scrub typhus than in murine typhus
(Table 1). In spotted fever group disease, the most important
pathophysiological effect of rickettsial infection is increased
vascular permeability with extravascular loss of albumin.
Whether this might play a role in scrub typhus as well
remains to be investigated.
Coagulation changes in scrub typhus patients were char-
acterized by an inflammation-induced coagulopathy, with
coagulation activation, AT depletion, increases in the levels
of proinflammatory cytokines and more pronounced CRP
levels than in murine typhus patients. The level of tissue
factor (TF), the main initiator of coagulation activation
through the so-called extrinsic pathway, was so promi-
nently raised in scrub typhus patients that it could be used
to correctly classify 97.5% of all patients in this study
(Table S1).
Proinflammatory cytokines such as TNF-a, IL-1b and IL-6
have been shown to induce TF expression on endothelial
cells [14] and mononuclear cells upon activation [15].
The association of O. tsutsugamushi with circulating mononu-
clear cells in vivo [16], and previous findings of elevated solu-
ble L-selectin levels in patients with scrub typhus, are both
suggestive of mononuclear cell activation [9], and CRP, the
level of which is more prominently increased in scrub typhus,
has been shown to facilitate monocyte–endothelial cell inter-
actions [17] and to promote PAI-1 and TF formation [18].
Despite the procoagulant profile of patients with scrub
typhus, no overt DIC was observed in this study, although
occasional case reports have described DIC in scrub typhus
[19].
The activation pattern in murine typhus patients followed
a distinct ‘endothelial perturbation profile’, with prominent
increases in the levels of endothelium-derived factors, includ-
ing VWF, sTM, tPA, and PAI-1. Thrombomodulin is an anti-
coagulant transmembrane glycoprotein and an endothelial
marker, and plasma levels of its proteolytically degraded sol-
uble form correlate with endothelial activation and organ
damage [20]. The sTM level was so prominently raised in
murine typhus patients, that, like sTF in scrub typhus
patients, it could be used to correctly classify 97.5% of all
patients in this study (Table S1).
Activated PC antagonizes TF-induced coagulation activa-
tion. PC is activated by thrombin when it is bound to
thrombomodulin on the endothelial surface, and inhibits
thrombin-mediated conversion of fibrinogen to fibrin, and
binding of thrombin to other cellular receptors on platelets
or inflammatory cells [21]. This anticoagulant PC system
appeared to be less active in murine typhus patients, with
significantly lower PC levels than in the other patient
groups (Fig. 2). The high concentrations of endothelium-
derived PAI-1 observed in murine typhus patients may
explain the decrease in overall fibrinolytic activity measured
as PAA despite the high concentrations of tPA in this group
(Fig. 4).
The plasma levels of cytokines were generally low, which
could be attributable to predominant local production at the
site of inoculation eschar and/or disseminated small foci of
infection with a dilution effect on the systemic compartment
[22]. The low levels of TNF-a and IL-1b observed upon
admission appear to be consistent with a previous study in
Vietnam, where TNF-a and IL-1b levels in scrub typhus
patients were undetectable in 90% and 75%, respectively
[23]. IL-10 levels were four-fold higher in scrub typhus than
in murine typhus patients, suggesting a stronger anti-inflam-
matory tendency with suppression of other inflammatory
cytokines such as TNF-a, IL-1b, and IL-6 (Table 2), especially
in bacteraemic patients with scrub typhus, who had signifi-
cantly higher IL-8 and IL-10 levels and significantly lower
PAA levels on admission, in contrast to murine typhus
patients, in whom no association between bacteraemia and
cytokine levels was noted. IL-10 can inhibit the expression
of major histocompatibility complex class II antigens, CD54
(ICAM-1), CD80 (B7.1), and CD86 (B7.2), on monocytes,
through a post-transcriptional mechanism. This could repre-
sent an immunomodulatory host–pathogen effect, as the T-
cell-activating capacity of monocyte antigen presentation is
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reduced [24]. Furthermore, IL-10 can attenuate activation of
the coagulation system, inhibit cytokine release, and potently
modulate the fibrinolytic system, resulting in an inhibition of
procoagulant responses in humans with induced endotoxa-
emia [25], thus raising further questions regarding its role in
scrub typhus.
This study highlighted the diagnostic and highly discrimina-
tory potential of these coagulation markers for scrub and
murine typhus (all p <0.0001; Table 2), as they correctly clas-
sified patients with either form of typhus. sTF at a cut-off of
‡387 pg/mL had the strongest predictive power for scrub
typhus, correctly classifying 97.5% of all patients (corre-
sponding to a sensitivity of 98.2% and a specificity of 97%),
and sTM scored highest for murine typhus, correctly classify-
ing 97.5% of all patients (sensitivity of 96.4% and specificity
of 98.5%) at the designated cut-off (Table S1; Fig. S2). These
findings warrant further investigations into the diagnostic
potential of these markers.
The endothelium-tropic spotted fever rickettsia R. rickettsii
(Rocky Mountain spotted fever) and R. conorii (Mediterra-
nean spotted fever) induce a procoagulant state, with upreg-
ulation of TF [26], downregulation of TM [27] and release
of both PAI-1 [28] and VWF [29] in cultured human endo-
thelial cells. These data support the profile seen in human
plasma samples from murine typhus patients in this study,
which is also in line with the evidence for the endothelial
tropism of R. typhi derived from in vitro experiments, mouse
studies, and human post-mortem studies [7,30]. However,
the pattern seen in scrub typhus supports a procoagulant
state with a less ‘endothelial’ but more inflammatory profile.
This could suggest more prominent mononuclear involve-
ment, which is supported by evidence of significantly higher
mononuclear cell activation in scrub than in murine typhus
[9]. Furthermore, dendritic and mononuclear cell infection
with O. tsutsugamushi could have a role in the disease pro-
cess beyond the early immune response, which may include
a role in early systemic dissemination (and replication?) via
circulation of these cell types beyond the skin inoculation
sites.
In conclusion, this study shows activation of coagulation in
both scrub and murine typhus patients as compared with
controls. In scrub typhus, coagulation activation is more
prominent and related to a stronger proinflammatory
response, whereas in murine typhus, changes in coagulation
and fibrinolysis follow a pattern suggestive of endothelial cell
perturbation. Further studies are needed to improve our
understanding of the pathophysiological changes underlying
these disease states, in order to improve diagnosis and ulti-
mately to help in the design of effective vaccines for both
typhus diseases.
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